Cost-effectiveness of polatuzumab vedotin in combination with chemoimmunotherapy (pola-R-CHP) in previously untreated diffuse large B-cell lymphoma in Germany

Swetha Kambhampati, Evgenii Shumilov, Monica Saumoy, Alex F. Herrera, Hervé Tilly, Georg Lenz, Nikhil R. Thiruvengadam

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)771-775
Number of pages5
JournalBritish Journal of Haematology
Volume202
Issue number4
DOIs
StatePublished - Aug 2023

ASJC Scopus Subject Areas

  • Hematology

Keywords

  • DLBCL
  • R-CHOP
  • cost-effectiveness analysis
  • lymphoma
  • pola-R-CHP

Cite this